Eikon Therapeutics, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Yeah, we've normally got a timer over there, so I'll just look at my phone periodically.
All right, let's do that.
Well, good afternoon, everyone. I'm Sean Laaman, head of U.S. Mid-Cap Biotech Equity Research here at Morgan Stanley, and welcome to the Morgan Stanley Global Healthcare Conference. Before we commence, to make you aware of some important disclosures, please go to the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have the pleasure of hosting from Eikon Therapeutics, their CEO, Roger Perlmutter, and CFO, Freddie Bowie. Thank you, gentlemen, for attending and look forward to the discussion.
Thank you, Sean, very much.
Yeah, thanks for having us.
Appreciate it. Yep. Thanks for doing this.
I've got a couple of macro questions to begin with.
Okay. Let's just punch through them and get to the meat, which is Eikon.
Okay. How is the rise of China-originated innovation changing, if at all, your competitive positioning and your R&D and BD playbook?
Well, I think that the rise of China has affected everybody in the industry, of course. I see that as a natural evolution. This has been going on for a very long time.
25 years ago, we watched as a flood of very high-quality Chinese graduate students made their way to the U.S. and were studying in American laboratories, or even further ago than that. It is only natural that many of those people, well-trained, experienced, decided there were opportunities in China that were superior, and there was a chance to harness an enormous amount of capability there. It is important to point out that the Chinese government has been investing heavily in this sector. It is understandable that you would expect to see a lot of innovation coming from China. There is a substrate there that enables that progressive increase in sophistication in China, so that whereas before one had concerns about GXP execution, how well compliance worked in the clinical setting, intellectual property issues.
I think more and more, we are just looking at another group that is very capable of producing high-quality material to be studied for the improvement of treatment of human disease. Which, as far as I am concerned, can only be a good thing, right? We expect to be in a global business forever, because around the world, patients are experiencing the same kinds of problems, and the more that we can do to improve treatment for such patients, the better off we are going to be. I embrace it. I think it just makes us better.
Sure. Wonderful. Thank you. A little bit unusual asking you gentlemen this question. It pertains to AI, and obviously AI is obviously embedded in your platform. But the question is, beyond that, are you implementing AI across other parts of your business? Can you point to a definitive outcome on influencing a decision, a cost outcome, or a POS?
Well, the reality is that AI affects every aspect of every business. Most of the work is quite prosaic. The fact that you have a trusted partner, if you will, that can write quite effectively grammatically correct English that is more or less submission-ready, of course saves an enormous amount of human time, which is great. Most of that, as I say, is relatively prosaic work.
For our business, as you point out, little Eikon is one of the largest data producers on the planet. The analysis of that data simply can't be done by human beings.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring